These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25884438)

  • 1. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer.
    Jedinak A; Curatolo A; Zurakowski D; Dillon S; Bhasin MK; Libermann TA; Roy R; Sachdev M; Loughlin KR; Moses MA
    BMC Cancer; 2015 Apr; 15():259. PubMed ID: 25884438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
    Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
    Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
    Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers.
    Zhang M; Chen L; Yuan Z; Yang Z; Li Y; Shan L; Yin B; Fei X; Miao J; Song Y
    Discov Med; 2016 Nov; 22(122):281-295. PubMed ID: 28009970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
    Zhao H; Zhao X; Lei T; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of urine-circulating miRNAs for detection of prostate cancer.
    Stuopelyte K; Daniunaite K; Bakavicius A; Lazutka JR; Jankevicius F; Jarmalaite S
    Br J Cancer; 2016 Sep; 115(6):707-15. PubMed ID: 27490805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of miRNAs in urine of prostate cancer patients.
    Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
    Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
    Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
    Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer.
    Byun YJ; Piao XM; Jeong P; Kang HW; Seo SP; Moon SK; Lee JY; Choi YH; Lee HY; Kim WT; Lee SC; Cha EJ; Yun SJ; Kim WJ
    Investig Clin Urol; 2021 May; 62(3):340-348. PubMed ID: 33834642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
    Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
    Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular RNAs from Whole Urine to Distinguish Prostate Cancer from Benign Prostatic Hyperplasia.
    Stella M; Russo GI; Leonardi R; Carcò D; Gattuso G; Falzone L; Ferrara C; Caponnetto A; Battaglia R; Libra M; Barbagallo D; Di Pietro C; Pernagallo S; Barbagallo C; Ragusa M
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
    Yan C; Kim YH; Kang HW; Seo SP; Jeong P; Lee IS; Kim D; Kim JM; Choi YH; Moon SK; Yun SJ; Kim WJ
    J Korean Med Sci; 2015 Dec; 30(12):1784-92. PubMed ID: 26713053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
    Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
    Fu S; Zhang X; Niu Y; Wang RT
    Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
    Wang W; He Z; Kong Y; Liu Z; Gong L
    Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
    Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S
    Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.